{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:27:13Z","timestamp":1787646433641,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016253","name":"Atara Biotherapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jbc.2026.113100","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:00:50Z","timestamp":1777590050000},"page":"113100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A tri-specific EGFR\/cMet\/VEGF antibody demonstrates potent multi-mechanistic activity in preclinical triple-negative breast cancer models"],"prefix":"10.1016","volume":"302","author":[{"given":"Pu","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhengXia","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"MacWilliams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6300-404X","authenticated-orcid":false,"given":"Mark L.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2026.113100_bib1","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2026.113100_bib2","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","article-title":"Measures of outcome in metastatic breast cancer: insights from a real-world scenario","volume":"19","author":"Bonotto","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.jbc.2026.113100_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2014.0008","article-title":"Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy","volume":"12","author":"Seah","year":"2014","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.jbc.2026.113100_bib4","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1158\/1078-0432.CCR-14-3122","article-title":"CCR 20th anniversary commentary: triple-negative breast cancer in 2015\u2014Still in the ballpark","volume":"21","author":"Narod","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2026.113100_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108253","article-title":"Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options","volume":"237","author":"So","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jbc.2026.113100_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jbc.2026.113100_bib7","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/annonc\/mdp062","article-title":"Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer","volume":"20","author":"Linderholm","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbc.2026.113100_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0974-2727.163129","article-title":"Epidermal growth factor receptor expression in triple negative and nontriple negative breast carcinomas","volume":"7","author":"Changavi","year":"2015","journal-title":"J Lab Physicians"},{"key":"10.1016\/j.jbc.2026.113100_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0974-2727.163129","article-title":"Epidermal growth factor receptor expression in triple negative and nontriple negative breast carcinomas","volume":"7","author":"Changavi","year":"2015","journal-title":"J. Lab Physicians"},{"key":"10.1016\/j.jbc.2026.113100_bib10","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10637-020-00937-y","article-title":"Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A","volume":"38","author":"Breen","year":"2020","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.jbc.2026.113100_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pharmthera.2011.03.012","article-title":"Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis","volume":"131","author":"Larsen","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jbc.2026.113100_bib12","doi-asserted-by":"crossref","first-page":"vii109","DOI":"10.1093\/annonc\/mdl962","article-title":"Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy","volume":"17","author":"Ciardiello","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbc.2026.113100_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e18072","article-title":"VEGF expression in cetuximab resistance development in patients with squamous cell carcinoma of the tongue and oral mucosa","volume":"40","author":"Lyanova","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113100_bib14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1091\/mbc.e04-07-0567","article-title":"HGF converts ErbB2\/Neu epithelial morphogenesis to cell invasion","volume":"16","author":"Khoury","year":"2005","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.jbc.2026.113100_bib15","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-07-4905","article-title":"Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells","volume":"14","author":"Bianco","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2026.113100_bib16","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/ijc.28566","article-title":"MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative\/basal-like breast cancer","volume":"134","author":"Kim","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbc.2026.113100_bib17","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1158\/0008-5472.CAN-14-0584","article-title":"Definition of PKC-alpha, CDK6, and MET as therapeutic targets in triple-negative breast cancer","volume":"74","author":"Hsu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2026.113100_bib18","doi-asserted-by":"crossref","first-page":"69903","DOI":"10.18632\/oncotarget.12065","article-title":"Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers","volume":"7","author":"Linklater","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbc.2026.113100_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3224","article-title":"Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met","volume":"14","author":"Mueller","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jbc.2026.113100_bib20","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/2326-6066.CIR-18-0070","article-title":"Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs","volume":"6","author":"Christmas","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jbc.2026.113100_bib21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10549-017-4102-2","article-title":"Angiopoietin pathway gene expression associated with poor breast cancer survival","volume":"162","author":"Ramanathan","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbc.2026.113100_bib22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1517\/13543784.17.7.997","article-title":"Targeting the c-MET signaling pathway for cancer therapy","volume":"17","author":"Liu","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jbc.2026.113100_bib23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3390\/cancers13051027","article-title":"A novel bispecific antibody targeting EGFR and VEGFR2 is effective against triple negative breast cancer via multiple mechanisms of action","volume":"13","author":"Mohan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbc.2026.113100_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462213","article-title":"In-capillary (electrophoretic) digestion-reduction-separation: a smart tool for middle-up analysis of mAb","volume":"1648","author":"Dadouch","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jbc.2026.113100_bib24","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.1158\/0008-5472.CAN-07-0696","article-title":"Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors","volume":"67","author":"Stavenhagen","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2026.113100_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1533059","article-title":"A trispecific antibody targeting EGFR\/cMET\/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models","volume":"15","author":"Jin","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbc.2026.113100_bib26","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jbc.2026.113100_bib27","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2026.113100_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CMAR.S316700","article-title":"The characteristics of tumor microenvironment in triple negative breast cancer","volume":"14","author":"Fan","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.jbc.2026.113100_bib33","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7150\/jca.9696","article-title":"cMET activation and EGFR-directed therapy resistance in triple-negative breast cancer","volume":"5","author":"Sohn","year":"2014","journal-title":"J. Cancer"},{"key":"10.1016\/j.jbc.2026.113100_bib31","doi-asserted-by":"crossref","first-page":"24689","DOI":"10.1074\/jbc.M115.651653","article-title":"Impact of cell-surface antigen expression on target engagement and function of an epidermal growth factor receptor \u00d7 c-MET bispecific antibody","volume":"290","author":"Jarantow","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.113100_bib29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2026.113100_bib30","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/bjc.1998.518","article-title":"The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas","volume":"78","author":"Velders","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbc.2026.113100_bib28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/intimm\/dxx025","article-title":"Diversification of IgG effector functions","volume":"29","author":"Bournazos","year":"2017","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jbc.2026.113100_bib34","article-title":"Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models","volume":"16","author":"Jin","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2026.113100_bib35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1073\/pnas.63.1.78","article-title":"The covalent structure of an entire gammaG immunoglobulin molecule","volume":"63","author":"Edelman","year":"1969","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.113100_bib36","series-title":"Sequences of Proteins of Immunological Interest","author":"Kabat","year":"1991"},{"key":"10.1016\/j.jbc.2026.113100_bib39","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1038\/nprot.2014.169","article-title":"Controlled Fab-arm exchange for the generation of stable bispecific IgG1","volume":"9","author":"Labrijn","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jbc.2026.113100_bib37","series-title":"Antibody Engineering","article-title":"Separation of monoclonal antibodies by analytical size exclusion chromatography","author":"Chakrabarti","year":"2018"},{"key":"10.1016\/j.jbc.2026.113100_bib40","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Karagiannis","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113100_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-009-0460-8","article-title":"Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines","volume":"121","author":"Hollestelle","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbc.2026.113100_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10549-017-4496-x","article-title":"Multidimensional phenotyping of breast cancer cell lines to guide preclinical research","volume":"167","author":"Saunus","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbc.2026.113100_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041264","article-title":"Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2","volume":"19","author":"Peach","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2026.113100_bib44","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1073\/pnas.87.4.1323","article-title":"Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line","volume":"87","author":"Conn","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.113100_bib45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/19420862.2016.1249079","article-title":"Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells","volume":"9","author":"Grugan","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.jbc.2026.113100_bib46","article-title":"Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.jbc.2026.113100_bib47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826019721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826019721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:36:12Z","timestamp":1787643372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925826019721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0021925826019721"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113100","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A tri-specific EGFR\/cMet\/VEGF antibody demonstrates potent multi-mechanistic activity in preclinical triple-negative breast cancer models","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"113100"}}